The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

CMS Lifts Outpatient Pay 2.3%, Cuts 340B Rates for 2027

CMS finalized its 2027 hospital outpatient and ambulatory surgical center payment rule on Nov. 4, setting the financial terms hospitals will operate under next year. According to Becker's Hospital Review, outpatient payment rates will rise 2.3% for hospitals that meet quality reporting requirements. That figure reflects a 3.2% market basket increase offset by a productivity adjustment.

The headline number masks several cuts. CMS is reducing payment for 340B-acquired drugs, a move that squeezes safety-net hospitals that rely on the discount program to stretch margins. The agency is also expanding site-neutral payments to imaging services, meaning hospital outpatient departments will be paid the same as physician offices for those procedures rather than commanding higher facility rates. CMS continues to phase out the inpatient-only list, pushing more procedures into the outpatient and ASC settings.

In practice, the pay bump will not fully cover inflation for many systems, and the 340B and site-neutral changes shift revenue away from hospitals toward lower-cost settings.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.